Bristol-Myers Squibb Co v Apotex Pty Ltd (No 5)

Link copied
Case Copied 65 min read

FEDERAL COURT OF AUSTRALIA

Bristol-Myers Squibb Company v Apotex Pty Ltd (No 5) [2013] FCA 1114

Citation: Bristol-Myers Squibb Company v Apotex Pty Ltd (No 5) [2013] FCA 1114
Parties: BRISTOL-MYERS SQUIBB COMPANY and OTSUKA PHARMACEUTICAL CO., LTD v APOTEX PTY LTD (ACN 096 916 148)
File number: NSD 1116 of 2009
Judge: YATES J
Date of judgment: 30 October 2013
Catchwords:

PATENTS – standard patent for improved form of anhydrous aripiprazole crystals having low hygroscopicity (Crystals B) – whether hygroscopicity is inherent property of given crystalline form of aripiprazole – whether disclosure of particular crystalline form of aripiprazole discloses its physicochemical properties including its hygroscopicity

PATENTS – validity – novelty – inevitable result – whether person skilled in the art carrying out directions in prior art patent specification before priority date would inevitably have obtained anhydrous aripiprazole crystals having the characteristic low hygroscopicity of Crystals B – whether directions in prior art patent specification disclose the invention as claimed

PATENTS – validity – novelty – whether disclosure of crystalline form of Crystals B in prior art publications discloses the invention as claimed – whether prior art publications should be treated as single source of information

PATENTS – validity – false suggestion or misrepresentation – statements in complete specification and correspondence in course of prosecuting application for patent

PATENTS – validity – inventive step – problem‑solution approach – whether person skilled in the art would be directly led as a matter of course to take steps that would lead to the invention as claimed

PATENTS – validity – manner of manufacture – whether working interrelationship between drug comprising Crystals B and commercial package carrying instructions for drug to be used to treat schizophrenia or its symptoms

PATENTS – validity – clarity – whether requirement that compound exhibits a particular endothermic peak is unclear for failure to specify whether one or more other endothermic peaks may also be present on analysis – whether requirement of mean particle size unclear for failure of claim to expressly stipulate a particular method of measuring mean particle size or range of particle sizes in a given sample

PATENTS – validity – fair basis – whether real and reasonably clear disclosure of Crystals B having certain particle size as part of invention

PATENTS – infringement – threatened infringement –contributory infringement – authorisation

PATENTS – standing to sue for infringement – whether first applicant is exclusive licensee of patent – right to manufacture aripiprazole under patent not conferred on licensee – consideration of meaning of “exclusive licensee”

Legislation: Copyright Act 1968 (Cth) s 101(1A)
National Health  Act 1953 (Cth)
Patents Act 1949 (UK)  s 101
Patents Act 1952 (Cth) ss 6, 96
Patents Act 1990 (Cth) ss 7, 13, 14, 18, 40, 117, 120(1), 138(3)
Cases cited: Aktiebolaget Hässle and Another v Alphapharm Pty Limited (2002) 212 CLR 411
Alphapharm Pty Ltd (ACN 002 359 739) v H Lundbeck A/S and Another (2008) 76 IPR 618
Apotex Pty Ltd (ACN 096 916 148) v Sanofi‑Aventis and Others
CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Bristol-Myers Squibb Co v Apotex Pty Ltd (No 5) and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2013] FCA 1114
Decision Date

CaseChat Overview and Summary

In the Federal Court, Bristol-Myers Squibb Co (BMS) brought proceedings against Apotex Pty Ltd (Apotex) concerning alleged patent infringement under the Patents Act 1990 (Cth). The central dispute revolved around the interpretation and scope of certain rights granted to BMS under a licensing agreement, and whether Apotex's activities constituted an infringement of those rights. The court was tasked with determining the specific nature of the rights conferred by the agreement, and whether Apotex's conduct fell within the scope of those rights, thereby constituting infringement.

The primary legal issue before the court was the interpretation of the licensing agreement between BMS and Apotex, specifically whether the agreement conferred exclusive rights or merely sole rights on BMS. The court also needed to assess the relevance and admissibility of certain pieces of evidence presented by both parties, including affidavits and recorded conversations. Additionally, the court had to consider the appropriateness of injunctive relief and declaratory relief in relation to the alleged infringement.

The court ruled that, while it was not necessary to definitively decide whether the agreement conferred exclusive or sole rights on BMS, it was inclined to interpret the agreement as granting exclusive rights. The court found that the language of the agreement did not indicate an intention to limit the rights to sole rights only. Regarding the evidence, the court admitted certain parts of the affidavits and recorded conversations, subject to relevance, and decided that they should be admitted unconditionally. The court indicated its provisional view that injunctive relief was appropriate, but declaratory relief regarding infringement might not be necessary. The court also noted the need for further submissions on specific aspects of the relief sought by BMS, particularly regarding the withdrawal of Apotex's application for pharmaceutical benefits scheme listing.

The court ordered the parties to prepare draft orders reflecting the reasons provided and indicated that further written submissions should be submitted if the parties could not agree on the orders. The court also allowed the parties' legal representatives a short period to review the reasons for any potential confidentiality claims before publication.

Orders

Orders of the court

Background

Background to the litigation

Evidence

Evidence Before The Court

In these circumstances, it is unnecessary for me to decide whether the Agreement confers exclusive rights or merely sole rights on BMS. Nevertheless, appreciating that a different view might be taken on the question I have decidedly adversely to BMS, I should state that, in respect of the rights in the Agreement that are expressed to be granted to BMS exclusively, there is nothing that indicates to me that only sole rights were intended to be granted.MISCELLANEOUS RULINGS ON EVIDENCE During the hearing, I made a small number of provisional rulings on evidence. The parties were content for me to provide final rulings in the course of providing these reasons. Paragraph 39 of Dr Rowe’s first affidavit and certain recorded conversations in paragraphs 176 and 177 of Associate Professor McGeary’s first affidavit were admitted, subject to relevance. I am satisfied that paragraph 39 of Dr Rowe’s first affidavit is relevant. The recorded conversations in paragraphs 176 and 177 of Associate Professor McGeary’s first affidavit seem to me to be of marginal relevance. I do not think, however, that those conversations stand apart from other parts of the affidavit with which they are associated and to which no objection on relevance (or, indeed, any objection) has been made. I will admit this evidence unconditionally.DISPOSITION The parties are to bring in draft orders reflecting these reasons. For the assistance of the parties, I should indicate my provisional view that, while injunctive relief is appropriate, declaratory relief in relation to infringement does not seem to be necessary or otherwise appropriate. I also note that an injunction is sought whose effect would be to require Apotex to withdraw its application to obtain listing of the Apotex products under the pharmaceutical benefits scheme maintained by the Commonwealth under the National Health Act 1953 (Cth). If that relief is to be pursued, and is opposed, I would wish to hear the parties further on that question. I have already indicated that I wish to hear the parties further on the infringement of claim 14, if that aspect of infringement is to be pursued. In the event that the parties are unable to agree on proposed orders to be made at the present time, written submissions, not to exceed three pages, should be provided to support the orders that each party contends should be made. I will then deal with the matter on the papers, unless I am persuaded that oral argument is required. Before publication of these reasons to the parties, and more generally, I will allow the parties’ external legal representatives a short period of time within which to consider whether these reasons include information in respect of which any remaining claim for confidentiality is made.

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established